US momentum leaders — September 2026

Kodiak Sciences' DAYBREAK win in wet AMD looks largely priced in, with the shares near the consensus target, deeply overbought and a launch still…

Iovance Biotherapeutics' raised FY2026 revenue guidance of $410–420 million, set two days before Q3 closed, still carries the case after a 229.5%…

GRAIL's shares already price in FDA approval of its Galleri cancer blood test and slipped to $132.61 on 8 October 2026 as new trial data arrived.…

Schrödinger's shares still trade well above the $20.80 consensus target after falling 11.3% to $28.90 on 6 October 2026, because software revenue…

Vicor Corporation's patent royalties on its Vertical Power Delivery technology drove two September guidance raises to more than 30% sequential…

American Outdoor Brands' 53.0% gross margin, raised profit guidance and $10 million buyback still support the shares, which closed at $16.30 on 8…

MaxLinear's shares fell 13% to $93.70 on 8 October 2026 after a 45% one-month rally yet still sit above the $88.64 average analyst target; the 22…

Cohu's AI-driven chip-test recovery has lifted the shares to $68.37, level with the $70.88 average analyst target; the Q3 report, expected about…

10x Genomics' shares, at $80.66 after a 17.5% one-day drop from a $97.74 high, still trade far above the business its new Atera instrument has yet…

Twist Bioscience's 23% revenue growth as an AI antibody-data supplier is real, but its shares fell to a $152.05 close on 8 October 2026, 25.8%…